Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20227920 | 0.80 | — | — | |
| SCHEMBL12053823 | 0.77 | BIRC2 (0.34) | CCR2 | |
| SCHEMBL12053826 | 0.77 | BIRC2 (0.34) | CCR2 | |
| SCHEMBL731706 | 0.77 | BIRC2 (0.34) | CCR2 | |
| SCHEMBL28274260 | 0.76 | ATM (0.31) | CCR2ATM | |
| Hydrochloric Acid SCHEMBL31094861 | 0.76 | CCR2 (0.33) | CCR2 | |
| SCHEMBL26604181 | 0.76 | ATM (0.31) | CCR2ATM | |
| SCHEMBL24429548 | 0.74 | CCR2 (0.33) | CCR2 | |
| SCHEMBL12044978 | 0.74 | CCR2 (0.33) | CCR2 | |
| SCHEMBL24429551 | 0.74 | CCR2 (0.30) | CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851115-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190002478-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002478-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | CCR2 640/4885ATM 4754/4885 |
| US-10851115-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | CCR2 640/4885ATM 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.